GW Pharmaceuticals Will Present Data From The Pivotal Phase 3 Trials Of Epidiolex Oral Solution, Cv In Lennox-Gastaut Syndrome And Dravet Syndrome, Along With Other Supportive Data, At The American Academy Of Neurology Annual Meeting, May 4-10